Daniela was thirty-one, an emergency medical technician in Phoenix, when her addiction medicine physician handed her something she had never seen before: a prescription for an app. Not a recommendation, not a suggestion, but an actual prescription written on a pad, transmitted to a specialty pharmacy, and accompanied by a unique access code. The app was reSET, an FDA-cleared prescription digital therapeutic for substance use disorder, and Daniela was supposed to use it twelve weeks alongside her standard outpatient counseling. The prescription confused her insurer’s customer service line for forty minutes. The pharmacy filled it within an hour. The cognitive behavioral modules became part of her recovery toolkit, accessed on her phone during overnight shifts when group therapy was impossible. She was an early American patient on a long, strange road of regulatory firsts and corporate failures, and her story is part of why the field of FDA digital therapeutics SUD looks the way it does in 2026.
The reSET and reSET-O Clearances
In September 2017, the U.S. Food and Drug Administration cleared reSET, a prescription digital therapeutic developed by Pear Therapeutics, for the treatment of substance use disorder. It was the first software-only product to receive FDA clearance with claims to improve clinical outcomes in disease. In December 2018, the agency cleared reSET-O, a companion product specifically for opioid use disorder when used alongside buprenorphine maintenance and outpatient treatment. Both clearances ran through the De Novo pathway, which the FDA uses for novel device categories without an established predicate.
The clearances were significant for several reasons. They established that interactive software delivering cognitive behavioral therapy could meet the FDA’s evidentiary standard for a medical device, they created a new prescription pathway for digital products dispensed through specialty pharmacies, and they validated the term prescription digital therapeutic as a regulatory category distinct from wellness apps and general consumer software. The pivotal trial for reSET showed meaningful improvements in abstinence and retention compared to standard treatment alone for patients with stimulant, alcohol, and cannabis use disorders.
The Pear Therapeutics Bankruptcy
Despite the regulatory victory, Pear Therapeutics filed for Chapter 11 bankruptcy in April 2023 and was wound down through a sale of assets. The company never achieved meaningful prescription volume relative to its overhead, payer reimbursement remained limited and inconsistent, the prescription pathway proved confusing for prescribers and pharmacists, and the burn rate of building a commercial digital pharma company exceeded what investors were willing to keep funding. The collapse sent a chill through the broader prescription digital therapeutic sector.
The lessons from Pear’s failure are still being absorbed across the industry. The product worked, the clearances were real, the clinical evidence was credible, and the company still failed because the commercial infrastructure of prescribing, dispensing, paying for, and supporting a software product through pharmacies was substantially more complex than building the software itself. FDA digital therapeutics SUD products that have followed have generally pursued more diversified distribution models. Our analysis of addiction technology trends traces how the field has evolved post-Pear.
Current FDA-Cleared Digital Therapeutics
Beyond reSET and reSET-O, several other prescription digital therapeutics hold active FDA clearance in 2026. The current roster, while imperfect and shifting, includes Somryst for chronic insomnia, EndeavorRx and EndeavorOTC for ADHD in pediatric patients, Rejoyn for major depressive disorder as an adjunct to antidepressant therapy, NerivioRx and Nerivio Migra for migraine, and Daylight for generalized anxiety disorder. Several pipeline products are in late-stage clinical trials, with FDA submissions expected in late 2026 and 2027.
- reSET (substance use disorder, including stimulants, alcohol, cannabis)
- reSET-O (opioid use disorder, adjunct to buprenorphine)
- Somryst (chronic insomnia in adults)
- EndeavorRx (ADHD in pediatric patients)
- Rejoyn (major depressive disorder, adjunct)
- Daylight (generalized anxiety disorder)
The current ownership of the Pear assets, including reSET and reSET-O, is in flux following the bankruptcy proceedings, and product availability has been intermittent. Patients and prescribers should verify current status with the manufacturer of record before initiating a prescription. The FDA device database at fda.gov maintains the authoritative list of cleared products and current sponsors.
Distinguishing Prescription From Wellness
The distinction between prescription digital therapeutics and consumer wellness apps is regulatory, evidentiary, and practical. Prescription digital therapeutics have completed clinical trials sufficient to meet FDA evidentiary standards for medical device clearance, carry specific clinical indications and contraindications, are dispensed through prescription with provider oversight, and may be subject to insurance coverage rules. Wellness apps make general claims about mood, sleep, or stress, are sold direct to consumer, do not require prescription, and are not regulated as medical devices.
Apps in the wellness category include Calm, Headspace, Reframe, Sunnyside, Sober Sidekick, and many others. Some of these have research evidence supporting general benefits, but none have FDA clearance to treat substance use disorder or any specific medical condition. They can be useful adjuncts but are not medical treatment. Our overview of recovery support apps walks through the wellness app ecosystem in detail.
Insurance Coverage Models
Reimbursement for prescription digital therapeutics has been the field’s biggest commercial challenge. Coverage approaches that exist today include classification as durable medical equipment, classification as a specialty pharmacy product analogous to a drug, value-based contracts with payer organizations, and direct contracts with employers and accountable care organizations. None of these has emerged as a dominant model, and the practical effect is that coverage varies dramatically by plan, by state, and by product.
The Access to Prescription Digital Therapeutics Act, introduced in Congress in multiple sessions, would explicitly authorize Medicare and Medicaid coverage for FDA-cleared prescription digital therapeutics. As of early 2026 the legislation has not passed, and reimbursement therefore remains plan-by-plan. Several state Medicaid programs have included prescription digital therapeutics in their pharmacy benefits, with mixed uptake. Commercial coverage continues to expand slowly.
The Prescription Pathway
For products that remain commercially active, the prescription pathway typically works as follows. The clinician determines that the patient is appropriate for the product based on its labeled indication. The clinician writes a prescription through the electronic health record, selecting the product from a digital therapeutics formulary. The prescription routes to a specialty pharmacy that dispenses the access code, often through email or text. The patient activates the code in the manufacturer’s app, completes onboarding, and begins the prescribed regimen. The clinician monitors engagement through a provider dashboard.
For substance use disorder products specifically, the prescription is generally written alongside ongoing outpatient treatment, including counseling and medication-assisted treatment where indicated. The digital therapeutic supplements rather than replaces standard care. SAMHSA guidance at samhsa.gov includes resources on integrating technology-based interventions into evidence-based addiction treatment.
The Future of Digital Therapeutics Post-Pear
The Pear collapse did not kill prescription digital therapeutics, but it did reshape the field. Companies that survived have generally adopted leaner operating models, more diversified payer strategies, and more aggressive direct-to-employer contracting. Several have de-emphasized the traditional pharmacy distribution model in favor of provider-administered access through electronic health records. Others have pursued FDA over-the-counter clearances, exemplified by EndeavorOTC, which removed the prescription requirement entirely while preserving the regulatory standing.
Post-Pear, three structural questions remain unresolved. First, will federal Medicare and Medicaid coverage expand systematically, or will it remain plan-specific? Second, will the prescription distribution channel survive, or will most products migrate toward provider-administered or OTC models? Third, will the evidence base for digital therapeutics deepen enough to drive guideline-level integration into clinical practice? The answers will define the next five years.
Practical Considerations for Patients
Patients considering a prescription digital therapeutic for substance use disorder should ask their prescribing clinician several practical questions: Is the product currently commercially available, given the post-Pear flux? Does my insurance cover it, and what is my out-of-pocket cost? How does the program integrate with my counseling and any medication-assisted treatment? What happens if my insurance denies coverage, and is there a manufacturer assistance program? Most important: what are the specific outcomes the product is meant to improve in my case?
For most patients, prescription digital therapeutics are an adjunct to comprehensive treatment, not a replacement for it. Standard evidence-based addiction care, including counseling, peer support, medication-assisted treatment where indicated, and recovery housing, remains the foundation. Digital products extend reach during nights, weekends, and travel, and may improve adherence to skills practice, but the human elements of treatment are still doing most of the work. Our companion piece on comprehensive outpatient SUD treatment covers the foundational care models.
Frequently Asked Questions
Are reSET and reSET-O still available?
Following the Pear bankruptcy, the assets including reSET and reSET-O have been acquired by other entities. Commercial availability has been intermittent. Patients and prescribers should verify current status before writing or filling prescriptions.
Is a wellness app like Headspace covered by insurance?
Generally no, although some employer wellness programs include subscriptions as a benefit. Wellness apps are not medical devices and are not eligible for reimbursement through medical insurance benefits.
Can a digital therapeutic replace counseling?
No FDA-cleared digital therapeutic for substance use disorder is approved as monotherapy. The labeled indications specify use alongside standard outpatient treatment, including counseling and medication-assisted treatment where appropriate.
Are there privacy concerns with digital therapeutics?
FDA-cleared products are subject to HIPAA when prescribed through a covered entity. Wellness apps are generally not. Patients should review privacy policies and understand what data is collected and shared, particularly given recent FTC enforcement actions against several mental health apps.
Can someone enroll without a prescription?
Prescription digital therapeutics by definition require prescription. Some products have transitioned to over-the-counter status, exemplified by EndeavorOTC for ADHD. Most SUD products remain prescription-only as of 2026.
The bottom line
The story of FDA-cleared digital therapeutics for substance use disorder is a regulatory success story attached to a commercial cautionary tale. The science behind reSET and reSET-O is real, the FDA clearances were legitimate, and the clinical outcomes were meaningful. The collapse of Pear Therapeutics in 2023 demonstrated that regulatory clearance and clinical efficacy are not sufficient to build a sustainable digital pharma company without solving the harder problems of distribution, reimbursement, and prescriber adoption. Patients in 2026 still have access to several FDA-cleared digital therapeutics for behavioral health conditions, including products specifically for substance use disorder, but availability is more uncertain and the field is in transition. The right way to think about these products is as medical-grade adjuncts to comprehensive treatment, prescribed thoughtfully and integrated into a broader recovery plan, not as replacements for human care or shortcuts around the slow work of building a life in recovery.
If you or someone you love is in suicidal crisis or experiencing a substance use crisis, call or text 988 to reach the 988 Suicide and Crisis Lifeline, or call SAMHSA’s National Helpline at 1-800-662-4357 for free, confidential, 24/7 treatment referral and information.
This article is for informational purposes only and does not substitute for medical advice. Decisions about prescription digital therapeutics should be made in consultation with a licensed clinician familiar with the patient’s complete treatment plan.